Leerink Partnrs Issues Optimistic Estimate for ARCT Earnings

Key Points

• Leerink Partners has raised its Q3 2025 earnings per share (EPS) estimate for Arcturus Therapeutics from ($0.88) to ($0.64), indicating improved financial expectations for the biotechnology firm.
• In its latest quarterly report, Arcturus Therapeutics reported an EPS of ($0.34), outperforming the consensus estimate of ($1.11) and generating revenue of $28.3 million, well above the expected $17.64 million.
• Despite some analysts lowering their target prices, the average rating for Arcturus Therapeutics' stock remains a "Moderate Buy" with a price target of $50.00.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for shares of Arcturus Therapeutics in a report released on Tuesday, August 12th. Leerink Partnrs analyst L. Nsongo now anticipates that the biotechnology company will post earnings of ($0.64) per share for the quarter, up from their previous forecast of ($0.88). The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($2.22) per share. Leerink Partnrs also issued estimates for Arcturus Therapeutics' Q4 2025 earnings at ($1.54) EPS, FY2025 earnings at ($3.04) EPS and FY2026 earnings at ($4.36) EPS.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.77. The firm had revenue of $28.30 million during the quarter, compared to the consensus estimate of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.

ARCT has been the subject of several other reports. Wells Fargo & Company lowered their target price on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating for the company in a research note on Tuesday. Wall Street Zen raised shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Canaccord Genuity Group lowered their price objective on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Citigroup reissued a "buy" rating and set a $49.00 price objective (up from $47.00) on shares of Arcturus Therapeutics in a research note on Tuesday. Finally, Scotiabank restated an "outperform" rating on shares of Arcturus Therapeutics in a report on Wednesday, July 2nd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, Arcturus Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $50.00.

Arcturus Therapeutics Stock Performance

ARCT stock opened at $19.21 on Thursday. The stock has a market capitalization of $521.74 million, a P/E ratio of -8.61 and a beta of 2.26. Arcturus Therapeutics has a one year low of $8.04 and a one year high of $25.88. The company has a 50 day moving average price of $13.29 and a two-hundred day moving average price of $13.30.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ARCT. Balyasny Asset Management L.P. acquired a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at about $9,312,000. Schonfeld Strategic Advisors LLC raised its stake in shares of Arcturus Therapeutics by 129.7% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company's stock valued at $14,409,000 after purchasing an additional 479,482 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at about $4,892,000. J. Goldman & Co LP acquired a new stake in shares of Arcturus Therapeutics in the 4th quarter valued at about $5,024,000. Finally, MPM Bioimpact LLC raised its stake in shares of Arcturus Therapeutics by 109.5% in the 4th quarter. MPM Bioimpact LLC now owns 459,943 shares of the biotechnology company's stock valued at $7,805,000 after purchasing an additional 240,435 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.